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A B S T R A C T
Role of various cytokines have been implicated in the development and perpetuation
of Sjögren's syndrome (SS), but no specific cytokine could be determined as a major con-
tributor to the SS. Salivary and serum interleukin 6 (IL-6) levels have been studied pre-
viously in patients with SS, but data upon salivary and serum basic fibroblast growth
factor (bFGF) in SS are lacking. The aim of this study was to evaluate levels of salivary
and serum IL-6 and bFGF in 18 patients with SS, age range 32–79, mean 54.05 years.
Control group consisted of 23 healthy participants, mean age 25 years. Serum IL-6 and
bFGF levels were not significantly different between patients with SS and healthy con-
trols. Elevated levels of salivary IL-6 and bFGF in patients with SS when compared to
the healthy controls were found (p<0.001). We might speculate that higher levels of sali-
vary IL-6 and bFGF in patients with SS might originate from local production probably
having source in the salivary glands.
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Introduction
Sjögren's syndrome (SS) is a chronic
inflammatory disorder characterized by
lymphocytic infiltration of lacrimal and
salivary glands, which results in dry eyes
and mouth1. Despite the extensive world-
wide literature, pathogenesis of SS re-
mains poorly understood. It has been pos-
tulated that a combination of immuno-
logic, genetic and environmental factors
are involved in the development of SS 2.
Interesting data on cytokine production
from the salivary glands of SS patients
have been reported in the past few years.
From reviewing the published literature
it is difficult to obtain a clear picture of
the cytokine profile in SS. This is largely
due to the major differences in techniques
and specimens used in these studies. All
the available data clearly suggest an in
situ immune response in the exocrine
glands of SS patients, with the epithelial
cell playing the role of antigen presenting
cell. As a consequence T-cells are attra-
cted and become activated. Produced cy-
tokines are responsible for inflammatory
perpetuation and stimulation of B-lym-
phocytes3.
The proinflammatory cytokine IL-6
play an important role in the inflamma-
tory, autoimmune and malignant pro-
cesses. IL-6 is generated by lymphocytes,
endothelial cells, fibroblasts and epithe-
lial cells. It is well known that collagen
diseases and other autoimmune diseases
are associated with elevated levels of se-
rum IL-64. Some authors5–7 found ele-
vated levels of salivary IL-6 in patients
with SS, but data upon serum IL-6 in SS
are scarce.
The role of basic fibroblast growth fac-
tor (bFGF) has been implicated in the nu-
merous processes of normal and neoplas-
tic tissues of the human and animal
bodies. BFGF has a pleiotrophic effects
and can act as a growth or differentiation
factor depending on the cell type and lo-
cal environment8. Various tissues from
ectodermal, endodermal and neural ori-
gin have been shown to produce bFGF
and serum bFGF levels are elevated in
patients with wide spectrum of tumors9–11.
There are few reports in the literature
which evaluate serum and salivary IL-6
levels in patients with SS, but no data
upon bFGF either salivary or serum in
patients with SS could be found in the
worldwide literature. The aim of this
study was to evaluate significance of sali-
vary and serum IL-6 and bFGF levels in
patients with SS.
Materials and Methods
Prior to investigation informed con-
sent according to FDA12 was obtained
from each participant. The patient group
consisted of 18 participants, all women,
with confirmed SS according to the Vitali
et al.13, revised version of the European
criteria set for classification. The patients
with SS were age range 32–79 years,
mean 54,05 years. Control group consist-
ed of 23 participants, 15 women and 8
men, mean age 25 who were healthy and
did not take any medications 1 month
prior to investigation.
Whole unstimulated saliva specimens
were collected from each participant
while they were sitting, into calibrated
tubes for five minutes according to Wu
Wang et al.14. Afterwards the saliva spec-
imens were stored at –70 °C and kept un-
til analysis. A 5 ml of fasting blood from
cubital vein was taken from each partici-
pant between 7 and 9 A.M., frozen and
stored at –70 °C until analysis.
For determination of salivary and se-
rum bFGF levels ELISA (Quantikine, HS
FGF basic, R&D Systems, Minneapolis,
USA) was performed. Concentrations of
salivary and serum IL-6 were determined
using an ELISA (Milenia Biotec, Bad Nau-
heim, Germany). Sensitivity for bFGF
was 0.22 pg/mL and for IL-6 was 1.2
pg/mL.
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Statistical analysis was performed us-
ing Mann Whitney U-test and values
lower than 0.001 were considered as sta-
tistically significant (p<0.001). The inves-
tigated parameters that did not show any
significance were then analyzed by use of
Mann Whitney U-test corrected for ties,
i.e. all the values that were zero were ex-
cluded from the analysis.
Results
No significant differences in serum
IL-6 values between patients with SS and
controls could be found.
No significant differences in serum
bFGF between patients with SS and con-
trols could be found using Mann-Whitney
U-test (Table 1).
Significant difference in salivary IL-6
between patients with SS and control
group was found by use of Mann-Whitney
U-test (p<0.001) (Table 2).
Significant difference in salivary bFGF
values between patients with SS and con-
trol group was found when Mann-Whit-
ney U-test corrected for ties was perfor-
med (p<0.001) (Table 3).
Discussion
Fox et al.15 evaluated IL-6 in labial
salivary glands in patients with SS with
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TABLE 1
DIFFERENCE OF SERUM BASIC FIBROBLAST GROWTH FACTOR (bFGF) BETWEEN











SS 18 17.78 320.00
Controls 17 18.24 310.00 149.000 0.895
Total 35
TABLE 2
DIFFERENCE OF SALIVARY INTERLEUKIN 6 (IL-6) BETWEEN PATIENTS WITH











SS 18 27.61 497.00
Controls 23 15.83 364.00 88.000 0.001
Total 41
TABLE 3
DIFFERENCE OF SALIVARY BASIC FIBROBLAST GROWTH FACTOR (bFGF) BETWEEN PATIENTS












SS 8 14.44 115.50 8.500 0.001
Controls 11 6.77 74.50
Total 19
oligonucleotide probes and in situ hybrid-
ization technique which demonstrated
that IL-6 mRNA was found both in infil-
trating lymphocytes and the epithelial
cells. Furthermore, Fox et al.5 reported
that IL-1 and IL-6 mRNA were found in
salivary gland epithelial cells using re-
verse transcriptase and polymerase chain
reaction. Oxholm et al.16 found greater
staining of duct cells with IL-6, IFN-,
and TNF- in labial salivary glands of SS
patients when compared to the normal
glands. Grisisus et al.7 found that sali-
vary IL-6 concentration was elevated in
patients with SS when compared to the
healthy subjects. As seen in our study,
the same authors found that higher IL-6
concentrations were associated with in-
creased disease activity. Also, salivary
levels were higher than serum levels in
patients with SS, and these findings sup-
port the contention that salivary IL-6 is
produced locally. Tischler et al.6 reported
that salivary IL-6 levels in the whole
mixed saliva were significantly elevated
in patients with primary SS when com-
pared to the patients with dry mouth, but
no significant differences in serum IL-6
were noticed between two groups. Same
authors also stated that elevated salivary
IL-6 levels are result of a local produc-
tion. Study of Fox et al.15 confirmed that
salivary IL-6 levels were significantly ele-
vated in the parotid saliva of patients
with SS when compared to the healthy
controls and patients with primary bi-
liary cirrhosis (PBC). On the contrary, se-
rum IL-6 were elevated in both SS and
PBC patients, although those levels were
less than those found in the saliva of the
same patients. Sun et al.17 stated that in-
creased gene expression of IL-6 was
found in patients with primary SS, but
that the IL-6 was also found in minor sal-
ivary glands in control subjects. Authors5–7
stated that increased salivary IL-6 levels
could accurately monitor salivary gland
involvement in SS patients. We have also
tried to evaluate the role of either sali-
vary and/or serum bFGF levels. The re-
sults of this study show that salivary
bFGF levels in patients with SS are ele-
vated when compared to the control
group. It is interesting to note that in pa-
tients with elevated salivary bFGF a fin-
ding of more active disease together with
additional systemic diseases was noticed.
Five patients with more active SS and
significantly elevated salivary bFGF
showed clinical and/or laboratory signs of
disease such as elevated erythrocyte sedi-
mentation rate, elevated levels of C-reac-
tive protein, decreased hemoglobin levels.
Patient GZ had also recurrent herpes
zoster infection together with SS. Patient
SD had also brain hemangioblastoma
and skin melanoma. Patient BA had ele-
vated serum IgM together with skin tu-
berculosis and liver cirrhosis. Patients
PM and CD had more active disease with
persistent SS-A levels more than 100 RU.
Serum bFGF levels were not signifi-
cantly different in patients with SS when
compared to the control group. These re-
sults would implicate a local production
of bFGF in patients with SS, but exact
place of bFGF origin remains to be eluci-
dated. In addition, elevated salivary
bFGF might be a result of a chronic in-
flammation, which might play a role in
the fibrosis seen in the later stages of
gland involvement. Furthermore, to our
knowledge no literature data upon sali-
vary and serum bFGF exist and our re-
sults are difficult to compare. Further
studies involving parotid and whole sa-
liva in patients with SS with regard to
IL-6 and bFGF levels are needed.
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ZNA^AJ SALIVARNOG I SERUMSKOG INTERLEUKINA 6 I BAZI^NOG
FAKTORA RASTA FIBROBLASTA U BOLESNIKA SA SJÖGRENOVIM
SINDROMOM
S A @ E T A K
Pretpostavlja se da uloga citokina mo`e biti uklju~ena u nastanak i razvoj Sjögre-
nova sindroma (SS), ali do sada niti jedan specifi~ni citokin nije naveden kao glavni
faktor koji doprinosi SS. Salivarni i serumski interleukin 6 (IL-6) su ve} prije ispitivani
u oboljelih od SS, dok podataka o salivarnom i serumskom bazi~nom faktoru rasta fi-
broblasta (bFGF) u oboljelih od SS nema. Cilj ovog ispitivanja je bio ustanoviti vri-
jednosti salivarnog i serumskog IL-6 i bFGF u 18 bolesnika sa SS, starosti 32–79, pro-
sje~ne starosti 54.05 godina. Kontrolna skupina se sastojala od 23 zdrava ispitanika,
srednje dobi 25 godina. Serumske vrijednosti IL-6 i bFGF se nisu zna~ajno razlikovale
u oboljelih od SS u odnosu na kontrolnu skupinu. Povi{ene vrijednosti salivarnog IL-6 i
bFGF su ustanovljene u oboljelih od SS u odnosu na kontrolnu skupinu (p<0.001).
Mo`emo zaklju~iti da povi{ene vrijednosti salivarnog IL-6 i bFGF u oboljelih od SS-a
mogu biti posljedica lokalne proizvodnje, vjerojatno unutar `lijezda slinovnica.
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